APA
García-Marco J. A., Jiménez J. L., Recasens V., Zarzoso M. F., González-Barca E., De Marcos N. S., Ramírez M. J., Parraga F. J. P., Yañez L., De La Serna Torroba J., Malo M. D. G., Ariznavarreta G. D., Persona E. P., Guinaldo M. A. R., De Paz Arias R., Llanos E. B., Jarque I., Valle M. D. C. F., Tatay A. C., De Oteyza J. P., Martin E. M. D., Fernández I. P., Martinez R. M., Costa M. A. A., Champ D., Suarez J. G., Díaz M. G., Ferrer S., Carbonell F. & García-Vela J. A. (20200713). High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. : Haematologica.
Chicago
García-Marco José A, Jiménez Javier López, Recasens Valle, Zarzoso Miguel Fernández, González-Barca Eva, De Marcos Nieves Somolinos, Ramírez M Jose, Parraga Francisco Javier Peñalver, Yañez Lucrecia, De La Serna Torroba Javier, Malo Maria Dolores Garcia, Ariznavarreta Guillermo Deben, Persona Ernesto Perez, Guinaldo M Angeles Ruiz, De Paz Arias Raquel, Llanos Elena Bañas, Jarque Isidro, Valle M Del Carmen Fernandez, Tatay Ana Carral, De Oteyza Jaime Perez, Martin Eva Maria Donato, Fernández Inmaculada Perez, Martinez Rafael Martinez, Costa M Angeles Andreu, Champ Diana, Suarez Julio García, Díaz Marcos González, Ferrer Secundino, Carbonell Félix and García-Vela José A. 20200713. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. : Haematologica.
Harvard
García-Marco J. A., Jiménez J. L., Recasens V., Zarzoso M. F., González-Barca E., De Marcos N. S., Ramírez M. J., Parraga F. J. P., Yañez L., De La Serna Torroba J., Malo M. D. G., Ariznavarreta G. D., Persona E. P., Guinaldo M. A. R., De Paz Arias R., Llanos E. B., Jarque I., Valle M. D. C. F., Tatay A. C., De Oteyza J. P., Martin E. M. D., Fernández I. P., Martinez R. M., Costa M. A. A., Champ D., Suarez J. G., Díaz M. G., Ferrer S., Carbonell F. and García-Vela J. A. (20200713). High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. : Haematologica.
MLA
García-Marco José A, Jiménez Javier López, Recasens Valle, Zarzoso Miguel Fernández, González-Barca Eva, De Marcos Nieves Somolinos, Ramírez M Jose, Parraga Francisco Javier Peñalver, Yañez Lucrecia, De La Serna Torroba Javier, Malo Maria Dolores Garcia, Ariznavarreta Guillermo Deben, Persona Ernesto Perez, Guinaldo M Angeles Ruiz, De Paz Arias Raquel, Llanos Elena Bañas, Jarque Isidro, Valle M Del Carmen Fernandez, Tatay Ana Carral, De Oteyza Jaime Perez, Martin Eva Maria Donato, Fernández Inmaculada Perez, Martinez Rafael Martinez, Costa M Angeles Andreu, Champ Diana, Suarez Julio García, Díaz Marcos González, Ferrer Secundino, Carbonell Félix and García-Vela José A. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. : Haematologica. 20200713.